Ravgen continues its legal revenge saga with a $57M verdict over Natera
Ravgen, a company that was a blip in prenatal screening not long ago, has continued its streak of legal victories against much larger companies thanks to another multimillion-dollar verdict.
A jury in the US District Court for the Western District of Texas decided that Natera must pay Ravgen $57 million for infringing on a Ravgen patent, the companies said on Tuesday.
In 2020, Ravgen embarked on a sprawling legal campaign and accused some of the biggest names in the testing business of copying its noninvasive prenatal test. The small company was awarded $375.5 million from Laboratory Corporation of America, better known as Labcorp, after a jury verdict and a judge’s order for punitive damages. Later, other lab giants — Quest Diagnostics, PerkinElmer and Illumina — settled for undisclosed sums.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.